Minster Pharmaceuticals plc (AIM: MPM), the drug development company specialising in neurological and psychiatric disorders, announces that following its Annual General Meeting which was held earlier today, all resolutions put to the shareholders were passed.

For further information:

Minster Pharmaceuticals plc                    Tel: +44 (0) 1799 506623

Paul Sharpe, Chief Executive Officer

Robert Aubrey, Chief Financial Officer

Buchanan Communications                       Tel: +44 (0) 20 7466 5000

Mark Court

Rebecca Skye Dietrich

Catherine Breen

Nomura Code Securities Limited             Tel: +44 (0) 20 7776 1200

Richard Potts

Gerard Harper

Notes for editors:

About Minster Pharmaceuticals plc

Minster Pharmaceuticals is a drug development company focussed on neurological and psychiatric disorders. Its principal pipeline assets are tonabersat, under development in the preventive treatment of migraine, and sabcomeline in schizophrenia. Worldwide rights to both compounds were acquired from GlaxoSmithKline and the compounds benefit from comprehensive safety tolerance data as a result of investment by GSK.

Tonabersat is the leading compound in an exciting new class of selective drugs designated as neuronal gap junction blockers and offers the potential to prevent the onset of migraine as a preferred alternative to acute treatment. Sabcomeline, a muscarinic partial agonist, has potential in the treatment of chronic schizophrenia.

Minster’s near-term focus is on the development and commercialisation of its current pipeline. Its medium term strategy is to leverage the anticipated cashflows from the current pipeline by in-licensing further compounds with the ultimate objective of creating a substantial and highly efficient drug development enterprise focussed on the central nervous system.

Minster joined the AIM market in February 2005 and trades under the symbol MPM. For further information please visit www.minsterpharma.com .